POM POMDOCTOR Ltd Annual reports only
Retail-Miscellaneous Retail · Nasdaq · SEC CIK 1877971 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY2025*2025-12-31 · USD | FY2024*2024-12-31 · CNY | FY2023*2023-12-31 · CNY |
|---|---|---|---|
| Income statement | |||
| Revenue | $57.19M | 342.56M | 304.85M |
| Cost of revenue | $49.71M | 294.86M | 266.13M |
| Gross profit | $7.48M | 47.69M | 38.72M |
| R&D expense | $1.84M | 3.00M | 3.37M |
| SG&A expense | $8.54M | 11.88M | 12.31M |
| Operating income | -$16.96M | -25.79M | -22.25M |
| Interest expense | $563,464 | 3.63M | 3.00M |
| Pretax income | -$18.72M | -37.37M | -36.95M |
| Income tax | $54 | — | — |
| Net income | -$18.72M | -37.39M | -36.95M |
| EBITDA | -$16.94M | -25.66M | -22.14M |
| EPS (basic) | -3.14 | -22.72 | -23.04 |
| EPS (diluted) | -3.14 | -22.72 | -23.04 |
| Weighted avg. shares (diluted) | 9.68M | 6.31M | 6.31M |
| Banking | |||
| Deposits | $1.35M | 7.60M | 6.68M |
| Balance sheet | |||
| Cash & equivalents | $1.37M | 7.65M | 6.72M |
| Receivables | $2.64M | 8.37M | — |
| Inventory | $1.18M | 9.17M | — |
| Current assets | $15.01M | 37.50M | — |
| PP&E, net | $178,257 | 461,362 | — |
| Total assets | $15.38M | 46.23M | — |
| Current liabilities | $31.20M | 179.15M | — |
| Short-term debt | $7.58M | 34.96M | — |
| Long-term debt | $11.70M | — | — |
| Total debt | $19.28M | — | — |
| Total liabilities | $84.21M | 545.91M | — |
| Shareholders' equity | -$64.92M | -2.26B | -2.12B |
| Net debt | $17.91M | — | — |
| Cash flow statement | |||
| Operating cash flow | -$21.23M | -16.13M | -45.80M |
| Capital expenditure | $144,107 | 37,773 | 111,891 |
| Free cash flow | -$21.38M | -16.17M | -45.91M |
| Investing cash flow | -$229,906 | -33,373 | -111,891 |
| Financing cash flow | $22.01M | 17.02M | 50.07M |
| Depreciation & amortization | $21,351 | 134,510 | 112,092 |
| Stock-based compensation | $2.35M | — | — |
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· This company uses different currencies across periods or line items (e.g. USD convenience translations in annual reports). Each column header shows its currency and cells in a different currency are marked; do not compare figures across currencies. Charts use only periods in the latest period's currency.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.